查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612149

胺基酸代谢紊乱治疗市场：按治疗、适应症和最终用户分类 - 全球预测 2025-2030

Amino Acid Metabolism Disorders Treatment Market by Treatment (Gene Therapy, Liver Transplant, Medication), Indication (Maple Syrup Urine Disease, Phenylketonuria), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胺基酸代谢紊乱治疗市值为7.969亿美元，预计到2024年将达到8.5117亿美元，复合年增长率为7.31%，到2030年将达到13.0641亿美元。

胺基酸代谢紊乱是一种遗传性疾病，会影响人体分解或加工胺基酸的能力，而胺基酸是蛋白质的重要组成部分。该市场的治疗范围包括营养食品、酵素替代疗法以及旨在调节或补偿功能失调的代谢途径的专用药物。对此类治疗的需求是因为它们有可能预防严重的健康问题，例如通常与这些疾病相关的神经病变、发育迟缓和器官功能障碍。应用涵盖儿科和成人患者群体，重点是早期诊断和长期管理策略。最终用途范围包括医院、专科诊所和居家照护机构，为受影响的个人提供全面的护理和支援。

主要市场统计
基准年[2023] 7.969 亿美元
预计年份 [2024] 85117万美元
预测年份 [2030] 1,306.41 百万美元
复合年增长率（%） 7.31%

影响该市场的关键成长要素包括代谢紊乱的盛行率日益增加、遗传和分子诊断的进步以及扩大公私倡议以提高意识和改善治疗机会。最近的潜在商机集中在新型治疗方法的开发上，特别是针对疾病遗传根源的基因编辑技术和个人化医疗策略。合成治疗性氨基酸和酶的合成生物学研究和创新也可以为业务成长铺平道路。鼓励公司投资合作研究伙伴关係并探索市场扩张，特别是在这些治疗方法的需求不断增加的开拓地区。

然而，该市场面临治疗开发成本高、监管挑战以及对这些疾病的认识低等限制，这可能会抑制市场进入和成长。遗传疾病的复杂性也对创造普遍有效的治疗方法提出了挑战。为了解决这些限制，对公共教育计画的策略性投资和支持卫生倡议的游说至关重要。市场竞争往往强调创新，创造了一个有可能出现专门针对罕见疾病的利基经营模式的环境。公司应专注于尖端研究和开发，与医疗保健提供者合作，并利用技术来优化供应链效率。

市场动态：揭示快速发展的胺基酸代谢紊乱治疗市场的关键市场洞察

供需的动态交互作用正在改变胺基酸代谢紊乱治疗的市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 越来越多的病例被诊断出患有氨基酸代谢紊乱，
    • 加强罕见代谢疾病监管措施
  • 市场限制因素
    • 由于治疗费用上涨而限制接触患者
  • 市场机会
    • 开发增强型诊断工具和基因检测技术
    • 正在进行的研究旨在发现氨基酸代谢紊乱的新治疗方法
  • 市场问题
    • 治疗胺基酸代谢紊乱的产品开发的复杂性

波特五力：引领胺基酸代谢紊乱治疗市场的策略工具

波特的五力架构是了解胺基酸代谢紊乱治疗市场竞争格局的关键工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解胺基酸代谢紊乱治疗市场的外部影响

外部宏观环境因素在塑造胺基酸代谢紊乱治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解胺基酸代谢紊乱治疗市场的竞争状况

胺基酸代谢紊乱治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：胺基酸代谢紊乱治疗市场供应商的绩效评估

FPNV 定位矩阵是评估胺基酸代谢紊乱治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製胺基酸代谢紊乱治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对氨基酸代谢紊乱治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胺基酸代谢紊乱的诊断不断增加
      • 加强支持性监管措施以应对罕见代谢疾病
    • 抑制因素
      • 高昂的治疗费用限制了患者的就诊
    • 机会
      • 开发增强型诊断工具和基因检测技术
      • 正在进行的研究旨在发现氨基酸代谢紊乱的新治疗方法
    • 任务
      • 治疗胺基酸代谢紊乱的产品开发的复杂性
  • 市场区隔分析
    • 治疗：增加药物的使用以去除体内多余的胺基酸
    • 最终使用者：透过医院和诊所扩大胺基酸代谢紊乱治疗的可近性，以诊断和治疗胺基酸代谢紊乱
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章胺基酸代谢紊乱治疗市场：依治疗分类

  • 介绍
  • 基因治疗
  • 肝臟移植
  • 药物治疗
  • 供应

第七章胺基酸代谢紊乱治疗市场：依适应症分类

  • 介绍
  • 枫糖尿症
  • 苯酮尿症

第八章胺基酸代谢紊乱治疗市场：依最终使用者分类

  • 介绍
  • 门诊手术中心
  • 医院/诊所

第九章北美和南美氨基酸代谢紊乱治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区胺基酸代谢紊乱治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲胺基酸代谢紊乱治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • PTC Therapeutics 在 SSIEM 2023 上展示苯酮尿症治疗的新进展
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Gene Therapies
  • Beacon Therapeutics Limited
  • Biogen Inc.
  • Cellectis SA
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-5D693B46BAC2

The Amino Acid Metabolism Disorders Treatment Market was valued at USD 796.90 million in 2023, expected to reach USD 851.17 million in 2024, and is projected to grow at a CAGR of 7.31%, to USD 1,306.41 million by 2030.

Amino acid metabolism disorders are genetic conditions that affect the body's ability to break down or process amino acids, which are essential building blocks of proteins. The scope of treatments in this market includes dietary supplements, enzyme replacement therapies, and specialized medications aimed at regulating or compensating for the dysfunctional metabolic pathways. The necessity for such treatments is driven by their potential to prevent serious health issues such as neurological impairment, developmental delays, and organ dysfunction typically associated with these disorders. Applications extend to both pediatric and adult patient populations, emphasizing early diagnosis and long-term management strategies. The end-use scope includes hospitals, specialty clinics, and homecare settings that provide comprehensive care and support for affected individuals.

KEY MARKET STATISTICS
Base Year [2023] USD 796.90 million
Estimated Year [2024] USD 851.17 million
Forecast Year [2030] USD 1,306.41 million
CAGR (%) 7.31%

Key influencing growth factors in this market include the increasing prevalence of metabolic disorders, advances in genetic and molecular diagnostics, and growing public and private initiatives to improve awareness and treatment access. The latest potential opportunities are centered on the development of novel therapies, especially gene editing technologies and personalized medicine strategies that target the disorder at its genetic root. Research and innovation into synthetic biology to engineer therapeutic amino acids or enzymes can also provide business growth avenues. Companies are recommended to invest in collaborative research partnerships and explore regional market expansions, particularly in underserved areas with rising demand for such treatments.

However, the market faces limitations such as high costs of treatment development, regulatory challenges, and a lack of widespread awareness about these disorders, which can impede market entry and growth. The complexity of genetic conditions also presents challenges in creating universally effective therapies. To address these limitations, strategic investment in public education programs and lobbying for supportive healthcare policies is essential. The nature of the market is competitive with a strong emphasis on innovation, creating fertile ground for niche business models focused on rare diseases. Companies should focus on cutting-edge R&D, partnerships with healthcare providers, and leveraging technology to optimize supply chain efficiencies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amino Acid Metabolism Disorders Treatment Market

The Amino Acid Metabolism Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of diagnosed cases of amino acid metabolism disorders,
    • Enhanced supportive regulatory policies addressing rare metabolic disorders
  • Market Restraints
    • High cost of treatment limiting patient accessibility
  • Market Opportunities
    • Development of enhanced diagnostic tools and genetic testing technologies
    • Ongoing research aimed at discovering new treatments for amino acid metabolism disorders
  • Market Challenges
    • Complexities in product development for amino acid metabolism disorders treatment

Porter's Five Forces: A Strategic Tool for Navigating the Amino Acid Metabolism Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amino Acid Metabolism Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amino Acid Metabolism Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amino Acid Metabolism Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amino Acid Metabolism Disorders Treatment Market

A detailed market share analysis in the Amino Acid Metabolism Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amino Acid Metabolism Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amino Acid Metabolism Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amino Acid Metabolism Disorders Treatment Market

A strategic analysis of the Amino Acid Metabolism Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amino Acid Metabolism Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, and Pfizer Inc..

Market Segmentation & Coverage

This research report categorizes the Amino Acid Metabolism Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Gene Therapy, Liver Transplant, Medication, and Supplementation.
  • Based on Indication, market is studied across Maple Syrup Urine Disease and Phenylketonuria.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of diagnosed cases of amino acid metabolism disorders,
      • 5.1.1.2. Enhanced supportive regulatory policies addressing rare metabolic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment limiting patient accessibility
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of enhanced diagnostic tools and genetic testing technologies
      • 5.1.3.2. Ongoing research aimed at discovering new treatments for amino acid metabolism disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in product development for amino acid metabolism disorders treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Growing usage of medications to eliminate excess amino acids from the body
    • 5.2.2. End-User: Growing accessibility of amino acid metabolism disorders treatment through hospitals & clinics for diagnosing and treating cases of amino acid metabolism disorders
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amino Acid Metabolism Disorders Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Gene Therapy
  • 6.3. Liver Transplant
  • 6.4. Medication
  • 6.5. Supplementation

7. Amino Acid Metabolism Disorders Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Maple Syrup Urine Disease
  • 7.3. Phenylketonuria

8. Amino Acid Metabolism Disorders Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgery Centers
  • 8.3. Hospitals & Clinics

9. Americas Amino Acid Metabolism Disorders Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Amino Acid Metabolism Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Amino Acid Metabolism Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. PTC Therapeutics to Showcase New Advances in Phenylketonuria Treatment at SSIEM 2023
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. American Gene Technologies Inc.
  • 4. Amgen Inc.
  • 5. AnGes, Inc.
  • 6. Astellas Gene Therapies
  • 7. Beacon Therapeutics Limited
  • 8. Biogen Inc.
  • 9. Cellectis SA
  • 10. Editas Medicine, Inc.
  • 11. F. Hoffmann-La Roche Ltd
  • 12. Ionis Pharmaceuticals, Inc.
  • 13. Merck KGaA
  • 14. Mustang Bio, Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY LIVER TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY SUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY MAPLE SYRUP URINE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY PHENYLKETONURIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. AMINO ACID METABOLISM DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023